Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain

Ugochukwu Agbakwuru; Jacob D. AuBuchon; Bobi Toebe; Anne LaBarge; Jorge Di Paola; Monica Hulbert

doi:10.1002/pbc.31458

Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain

Ugochukwu Agbakwuru, Jacob D. AuBuchon, Bobi Toebe, Anne LaBarge, Jorge Di Paola, Monica Hulbert

Research output: Contribution to journal › Article › peer-review

Abstract

Sickle cell disease (SCD) vaso-occlusive episode (VOE) pain is treated with opioids, and non-opioid adjuvants may reduce pain severity without opioid side effects. We retrospectively investigated the safety and tolerability of intravenous lidocaine infusions as an adjunct to opioids in children and adolescents during VOE hospitalizations. In 2 years, lidocaine was administered in 64.6% of 260 admissions. There were no serious toxicities; overall, 82.2% of recipients chose to receive lidocaine during subsequent admissions. Lidocaine infusions were associated with longer hospitalizations, potentially reflecting selection bias. The efficacy of adjuvant lidocaine infusions during VOE should be studied prospectively.

Original language	English
Journal	Pediatric Blood and Cancer
DOIs	https://doi.org/10.1002/pbc.31458
State	Accepted/In press - 2024

Keywords

opioid
pain management
sickle cell disease
vaso-occlusive pain

Access to Document

10.1002/pbc.31458

Cite this

@article{82f9671102804cc4a3bf0d9376310851,

title = "Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain",

abstract = "Sickle cell disease (SCD) vaso-occlusive episode (VOE) pain is treated with opioids, and non-opioid adjuvants may reduce pain severity without opioid side effects. We retrospectively investigated the safety and tolerability of intravenous lidocaine infusions as an adjunct to opioids in children and adolescents during VOE hospitalizations. In 2 years, lidocaine was administered in 64.6% of 260 admissions. There were no serious toxicities; overall, 82.2% of recipients chose to receive lidocaine during subsequent admissions. Lidocaine infusions were associated with longer hospitalizations, potentially reflecting selection bias. The efficacy of adjuvant lidocaine infusions during VOE should be studied prospectively.",

keywords = "opioid, pain management, sickle cell disease, vaso-occlusive pain",

author = "Ugochukwu Agbakwuru and AuBuchon, {Jacob D.} and Bobi Toebe and Anne LaBarge and {Di Paola}, Jorge and Monica Hulbert",

note = "Publisher Copyright: {\textcopyright} 2024 Wiley Periodicals LLC.",

year = "2024",

doi = "10.1002/pbc.31458",

language = "English",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

}

TY - JOUR

T1 - Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain

AU - Agbakwuru, Ugochukwu

AU - AuBuchon, Jacob D.

AU - Toebe, Bobi

AU - LaBarge, Anne

AU - Di Paola, Jorge

AU - Hulbert, Monica

PY - 2024

Y1 - 2024

N2 - Sickle cell disease (SCD) vaso-occlusive episode (VOE) pain is treated with opioids, and non-opioid adjuvants may reduce pain severity without opioid side effects. We retrospectively investigated the safety and tolerability of intravenous lidocaine infusions as an adjunct to opioids in children and adolescents during VOE hospitalizations. In 2 years, lidocaine was administered in 64.6% of 260 admissions. There were no serious toxicities; overall, 82.2% of recipients chose to receive lidocaine during subsequent admissions. Lidocaine infusions were associated with longer hospitalizations, potentially reflecting selection bias. The efficacy of adjuvant lidocaine infusions during VOE should be studied prospectively.

AB - Sickle cell disease (SCD) vaso-occlusive episode (VOE) pain is treated with opioids, and non-opioid adjuvants may reduce pain severity without opioid side effects. We retrospectively investigated the safety and tolerability of intravenous lidocaine infusions as an adjunct to opioids in children and adolescents during VOE hospitalizations. In 2 years, lidocaine was administered in 64.6% of 260 admissions. There were no serious toxicities; overall, 82.2% of recipients chose to receive lidocaine during subsequent admissions. Lidocaine infusions were associated with longer hospitalizations, potentially reflecting selection bias. The efficacy of adjuvant lidocaine infusions during VOE should be studied prospectively.

KW - opioid

KW - pain management

KW - sickle cell disease

KW - vaso-occlusive pain

UR - http://www.scopus.com/inward/record.url?scp=85211491307&partnerID=8YFLogxK

U2 - 10.1002/pbc.31458

DO - 10.1002/pbc.31458

M3 - Article

C2 - 39663785

AN - SCOPUS:85211491307

SN - 1545-5009

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

ER -

Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this